Transforming Molecular Diagnostics

Rapid Detection of Infectious Diseases

Rapid and comprehensive detection of pathogens is an important strategy in reducing the spread of infectious disease. Our EasyScreen™ Detection Kits identify a larger number of pathogen targets in a shorter time frame than conventional methods.

Efficient Workflow

Traditional techniques for identifying viral, bacterial and protozoan pathogens require a high degree of knowledge and can take days to get a result. Our EasyScreen™ Detection Kits replace these methodologies with a single efficient workflow that requires less training, staff and hands-on-time, and gives a result in under 5 hours.

Automatable

The Genetic Signatures GS1 platform is a high-throughput bench top platform that performs both nucleic acid extraction and automated 384-well PCR set-up for the entire EasyScreen™ range. Our EasyScreen™ Detection Kits are also compatible with most existing automated nucleic acid extraction and real-time PCR instruments.

Standardised Sample Processing

Our EasyScreen™ Sample Processing Kits offer streamlined preparation of nucleic acids direct from the primary specimen. Our sample processing method is common for all specimen types leading to workflow efficiencies and standardised results between laboratories.

3base™ Multiplex Technology

Our 3base™ technology forms the basis of the EasyScreen™ Detection Kits. 3base™ allows for simpler design of molecular assays facilitating the simultaneous detection of multiple targets. 3base™ is compatible with both RNA and DNA targets.

Product Pipeline

Genetic Signatures has a number of new detection kits in development. All new products follow a defined development and commercialisation process comprised of (i) Experimental Analytical Validation, and (ii) Clinical and Regulatory Validation prior to release.

Date of 2018 Annual General Meeting of Shareholders (GSS: ASX)

| ASX Announcements, Latest News | No Comments

Genetic Signatures Limited (ASX: GSS) has announced its date of 2018 Annual General Meeting. For more information click the link Date of Annual General Meeting 2018  

Genetic Signatures’ CEO Dr. John Melki interview by Proactive Investors

| ASX Announcements, Latest News | No Comments

Genetic Signatures’ CEO Dr. John Melki was recently interviewed by Proactive investors at the ASX Small and Mid-Cap Conference. See the link below to learn more about our 3baseTM technology and…

Genetic Signatures article from The Australian Financial Review.

| ASX Announcements, Latest News | No Comments

Genetic Signatures featured in The Australian Financial Review. For more information click the link:  Winning the war on superbugs

Genetic Signatures’ CEO Dr. John Melki presenting at the inaugural ASX Small and Mid-Cap Conference 6th September, Sydney, Australia.  

| ASX Announcements, Latest News | No Comments

Join ASX for the inaugural ASX Small and Mid-Cap Conference, showcasing emerging leaders in the small and mid-cap category. This is a unique opportunity to hear from a broad range…